Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SENSITIVITYMARKERS

Financiado

Cerrado

Clinical validation of prognostic biomarkers of chemotherapy response in liquid...

Clinical validation of prognostic biomarkers of chemotherapy response in liquid biopsies The lack of clinically validated biomarkers to properly select patients for treatment with anti-cancer agents remains a major problem. Patients are not always receiving the most optimal treatment, resulting in poor response rates... ver más

30/06/2015

NTRC

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NETHERLANDS TRANSLATIONAL RESEARCHCENTER BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-06-30

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NTRC

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PREDICT THE DRUG Using ex vivo functional genomics as biomarker to predict th... 150K€ Cerrado

MaGMa Applying Metabolomics to Unveil follow up treatment biomarke... 158K€ Cerrado

MoP-MiP Molecular Programming for MicroRNA profiling 1M€ Cerrado

RESICT-PC Studying Resistance to Cancer Therapeutics in Prostate Cance... 231K€ Cerrado

PHRD The development of Personalised Host Response Diagnostic kit 150K€ Cerrado

CROC The natural K, Fe, and Cu isotopic response to Pt-based chem... 176K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2014-12-18
Fecha Fin: 2015-06-30

Líder del proyecto

NETHERLANDS TRANSLATIONAL RESEARCHCENTER BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The lack of clinically validated biomarkers to properly select patients for treatment with anti-cancer agents remains a major problem. Patients are not always receiving the most optimal treatment, resulting in poor response rates and high societal costs. By profiling more than hundred drugs on a broad panel of genetically characterized cell lines, researchers from NTRC have identified novel predictive drug response biomarkers for several anti-cancer agents. In the feasibility (Phase 1) study two of these genomic drug sensitivity markers will be validated using whole genome sequencing data of patients treated with the corresponding agents. In addition, a protein kinase that is involved in glucocorticoid resistance in T-cell leukemia will be validated. Proliferation assays will be carried out with blood samples from leukemia patients using proprietary inhibitors that NTRC has developed against this kinase. After successful completion of Phase 1, the project will be extended to other drug sensitivity markers identified by cancer cell line profiling in Phase 2 of the project. In addition, assays to determine the mutant status of cancer genes in circulating DNA and miniaturized proliferation assays with patient blood cells will be developed. In the commercialization phase of the project, novel clinically validated biomarkers and assays for several anti-cancer drugs will be licensed to pharmaceutical and diagnostic companies. The results of the feasibility project will increase the value of NTRC’s biomarker discovery platform, resulting in a doubling of turn-over within two years. In addition, novel IP will be generated and licensed to pharmaceutical and diagnostic companies. After six years an ROI of seven times the initial investment is estimated. Overall, the project will result in increased clinical availability of genomic biomarkers, contribute to an overall improvement of cancer therapy, and increased sustainability of health care systems in the EU.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores